Hims Weight Loss Program: Eligibility, Medication Options, Pricing

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables behind every metabolic decision. Browse all Peptides & GLP-1 education

This review is editorially independent. PlexusDx has no commercial relationship with Hims or its parent company, and no affiliate links or paid placement are involved.

This review takes a program-level view of the Hims weight loss offering: who it is built for, the medication options inside it, how oversight and fulfillment work, what a member actually pays, and the metabolic starting point the program never measures. Fair-balance editorial framing — not a buying recommendation. Current as of April 2026.

Who the program is built for

Hims (Hims & Hers Health) is subscription telehealth aimed at adults seeking clinically supervised weight management without an in-person clinic. Eligibility is determined by a licensed provider from your submitted intake — weight, medical history, and current medications — rather than assumed at sign-up. Suitability, not enrollment, is the gate.

The medication options inside the program

Programs in this model center on the GLP-1 class: GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, and the GIP/GLP-1 dual agonist tirzepatide. Depending on eligibility and the pharmacy pathway, an option may be an FDA-approved brand product or a compounded semaglutide or tirzepatide formulation. Review the current menu on Hims's official website.

Provider oversight and the pharmacy pathway

The workflow is consistent across telehealth GLP-1 programs: (1) you complete an intake; (2) a licensed clinician reviews it and, if you qualify, issues a prescription; (3) the prescription routes to a retail pharmacy for a brand product or a 503A compounding pharmacy for a compounded one; (4) follow-up supports dose titration and side-effect management. Provider type and pharmacy partner vary by program.

What you actually pay each month

There is no single price — the total reflects product choice, subscription tier, and branded-versus-compounded fulfillment. Across the telehealth GLP-1 market as of April 2026, all-in monthly totals commonly range from roughly $200 to $700+, with wide variance. Because these figures move often, confirm current pricing on Hims's official website before enrolling.

What the trials behind the medications found

The program's medications rest on published evidence: STEP (semaglutide for weight management, The New England Journal of Medicine, 2021), SURMOUNT (tirzepatide for weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). Trial populations and endpoints differ, and outcomes vary from person to person.

The metabolic starting point the program does not measure

A weight loss program prescribes a compound; it does not read the genetics that compound acts on. Variants in FTO (fat-mass and obesity-associated), GLP1R (the GLP-1 receptor target), MC4R (satiety and energy balance), and TCF7L2 (glucose homeostasis and GLP-1 secretion) map your baseline metabolic terrain. They are pathway-level — not a prediction of drug response, but a description of the biology a clinician prescribes into.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. Before any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including FTO, MC4R, and TCF7L2 — so a program decision starts from your baseline biology. That is the test before you invest approach.

Not affiliated: PlexusDx has no affiliation or commercial relationship with Hims or the companies referenced here.

Disclaimer: This editorial review is for information only. PlexusDx is not affiliated with Hims and dispenses semaglutide and tirzepatide through its own Weight Management Protocols; this piece compares approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the PlexusDx approach: see the Weight Management Protocols, or start upstream and take the Precision Peptide Genetic Test to understand your GLP-1 pathway first.

Frequently Asked Questions

Who qualifies for the Hims weight loss program?

Eligibility is decided by a licensed clinician reviewing your intake — weight, medical history, and current medications — not by sign-up alone. Criteria vary by program and can change, so confirm the current requirements on the brand's own website before assuming you qualify for a GLP-1 prescription.

What medications does the program offer?

Telehealth GLP-1 programs typically offer semaglutide or tirzepatide, dispensed as an FDA-approved brand product or a compounded formulation through a 503A pharmacy, depending on eligibility. The exact menu changes over time; verify the current options and pharmacy pathways on the brand's own site.

How much does the program cost per month?

There is no flat fee. Across the telehealth GLP-1 market as of April 2026, monthly totals commonly range from roughly $200 to $700+, driven by product, subscription tier, and branded-versus-compounded fulfillment. Pricing is published on the brand's own site and changes frequently, so verify before enrolling.

Does genetic testing replace a weight loss program?

No. The Precision Peptide Genetic Test is not a program or a prescription and does not predict drug response. It maps pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline metabolic biology — upstream context that informs a conversation with your provider before any program begins.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.